Sign in

Lost your password?
(close)

Resources





Switzerland, long held up as an innovation powerhouse able to hold its own against the considerably larger neighbouring life science markets of France and Germany, has, in some respects, found the going tougher of late. The country’s domestic drug market has been enduring…

A bastion of equality with high levels of healthcare spending, excellent research and universities, a global commitment to improving health outcomes, and a deeply entrenched digital footprint, Norway is full of potential as a life sciences investment destination. This…

The inaugural edition of the US Healthcare and Life Sciences Review has collated comments and insights from stakeholders across regulators, health insurers, pharma and biotech companies, as well as patient and industry associations, to provide an incisive snapshot of the US…

A major new report led by the Novartis Foundation and Microsoft shows how investment in data and AI is critical to drive the health system improvements needed to respond to and recover from the COVID-19 pandemic and the world’s other greatest healthcare challenges.…

HCLS Review USA Data is an extensive compilation of data and infographics from the world’s largest and most important pharmaceutical market. US sales of drugs accounted for 48 percent of the global market for pharmaceuticals in 2019 and pharma market spending is on the…

In our second edition of InFocus Five Biotechs to Watch in China, we profile five biotech companies that have all found their own differing routes to success. While it is always tricky to define the starting point of a revolution, the Chinese biopharma boom – whether one…

We use cookies to ensure that we give you the best experience on our site. For more info click here